Ceribell CTO Raymond Woo sells $119,145 in company stock

Sunnyvale, CA – Raymond Woo, Chief Technology Officer at Ceribell, Inc. (NASDAQ:CBLL), disposed of 4,887 shares of common stock on October 1, 2026, for a total value of $119,145. The shares were sold at a price of $24.38 each. The stock has delivered a remarkable 100% return over the past year and currently trades near its 52-week high of $25.63, though InvestingPro analysis suggests the shares may be overvalued at current levels based on its Fair Value assessment.

The sale followed the exercise of stock options for a total of 4,887 shares of common stock. Of these, 4,864 shares were acquired at an exercise price of $3.65 per share, and an additional 23 shares were acquired at $4.70 per share. The total value of these acquired shares amounted to $17,861, with prices ranging between $3.65 and $4.70. All options exercised were fully vested and currently exercisable.

These transactions were conducted pursuant to a Rule 10b5-1 trading plan, which Mr. Woo adopted on June 5, 2026. Following these reported transactions, Mr. Woo directly beneficially owns 203,118 shares of Ceribell common stock. While the company boasts impressive gross profit margins of 89%, InvestingPro Tips indicate analysts don’t anticipate profitability this year. For deeper insights, investors can access Ceribell’s comprehensive Pro Research Report, available for this and 1,400+ other US equities.

In other recent news, Ceribell has seen multiple updates from analyst firms regarding its stock price target. TD Cowen analyst Joshua Jennings raised the price target for Ceribell shares to $33.00 from $29.00, maintaining a Buy rating, following a virtual call with the company’s CEO and CFO. BTIG reiterated a Buy rating and set a $30.00 price target after investor meetings that discussed Ceribell’s commercial strategy and expansion plans. Furthermore, Raymond James increased its price target to $29.00 from $24.00, citing new growth drivers expected to enhance the company’s utilization and impact consensus estimates positively. BTIG also raised its price target to $30 from $28, acknowledging Ceribell’s leadership in point-of-care rapid EEG technology. These developments highlight the company’s ongoing progress and the positive outlook from multiple analysts.